As Novo and Lilly Focus on a Few Big Markets, Sanofi Seeks Global Reach for Diabetes GLP-1 Drug

Experts say Novo Nordisk and Eli Lilly’s GLP-1 drugs are unlikely to reach more countries in the near term, but Sanofi’s diabetes treatment has gained ground globally.